JNK3 Inhibitors As Promising Pharmaceuticals with Neuroprotective Properties

Overview

Journal Cell Adh Migr

Specialty Cell Biology

Date 2024 Feb 15

PMID 38357988

Authors

Yibeini Wu

Yiling Zhao

Ziman Guan

Sajjad Esmaeili

Zhicheng Xiao

Diji Kuriakose

Affiliations

Soon will be listed here.

Abstract

The intensive study and investigation of neuroprotective therapy for central nervous system (CNS) diseases is ongoing. Due to shared mechanisms of neurodegeneration, a neuroprotective approach might offer benefits across multiple neurological disorders, despite variations in symptoms or injuries. C-Jun N-terminal Kinase 3 (JNK3) is found primarily in the CNS and is involved in physiological processes such as brain development, synapse formation, and memory formation. The potential of JNK3 as a target for pharmacological development holds promise for advancing neuroprotective therapies. Developing small molecule JNK3 inhibitors into drugs with neuroprotective qualities could facilitate neuronal restoration and self-repair. This review focuses on elucidating key neuroprotective mechanisms, exploring the interplay between neurodegenerative diseases and neuroprotection, and discussing advancements in JNK3 inhibitor drug development.

Citing Articles

Oxazine drug-seed induces paraptosis and apoptosis through reactive oxygen species/JNK pathway in human breast cancer cells.

Kim N, Dukanya D, Sethi G, Girimanchanaika S, Yang J, Nagaraja O Transl Oncol. 2024; 49:102101.

PMID: 39159553 PMC: 11380389. DOI: 10.1016/j.tranon.2024.102101.

References

Zheng K, Iqbal S, Hernandez P, Park H, LoGrasso P, Feng Y . Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives. J Med Chem. 2014; 57(23):10013-30. PMC: 4266361. DOI: 10.1021/jm501256y. View

Chen Q, Tu Y, Mak S, Chen J, Lu J, Chen C . Discovery of a novel small molecule PT109 with multi-targeted effects against Alzheimer's disease in vitro and in vivo. Eur J Pharmacol. 2020; 883:173361. DOI: 10.1016/j.ejphar.2020.173361. View

Wu Q, Wu W, Jacevic V, Franca T, Wang X, Kuca K . Selective inhibitors for JNK signalling: a potential targeted therapy in cancer. J Enzyme Inhib Med Chem. 2020; 35(1):574-583. PMC: 7034130. DOI: 10.1080/14756366.2020.1720013. View

Johnson G, Lapadat R . Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298(5600):1911-2. DOI: 10.1126/science.1072682. View

Dai W, Bao Y, Fan J, Li S, Zhao W, Yu B . Levocorydalmine attenuates microglia activation and neuropathic pain by suppressing ASK1-p38 MAPK/NF-κB signaling pathways in rat spinal cord. Reg Anesth Pain Med. 2020; 45(3):219-229. DOI: 10.1136/rapm-2019-100875. View

Liu C, Zhang C, Zhou Y, Wong W, Lee L, Ong W . APP upregulation contributes to retinal ganglion cell degeneration via JNK3. Cell Death Differ. 2017; 25(4):663-678. PMC: 5864187. DOI: 10.1038/s41418-017-0005-3. View

Feng Y, Park H, Bauer L, Ryu J, Yoon S . Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors. ACS Med Chem Lett. 2021; 12(1):24-29. PMC: 7812606. DOI: 10.1021/acsmedchemlett.0c00533. View

Zhao Y, Kuca K, Wu W, Wang X, Nepovimova E, Musilek K . Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases. Alzheimers Dement. 2021; 18(1):152-158. DOI: 10.1002/alz.12370. View

Zhang W, Liu H . MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002; 12(1):9-18. DOI: 10.1038/sj.cr.7290105. View

10.

Marmolejo-Martinez-Artesero S, Casas C, Romeo-Guitart D . Endogenous Mechanisms of Neuroprotection: To Boost or Not to Boost. Cells. 2021; 10(2). PMC: 7916582. DOI: 10.3390/cells10020370. View

11.

Zhang T, Inesta-Vaquera F, Niepel M, Zhang J, Ficarro S, Machleidt T . Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012; 19(1):140-54. PMC: 3270411. DOI: 10.1016/j.chembiol.2011.11.010. View

12.

Bruckner S, Tammariello S, Kuan C, Flavell R, Rakic P, Estus S . JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons. J Neurochem. 2001; 78(2):298-303. DOI: 10.1046/j.1471-4159.2001.00400.x. View

13.

Rehfeldt S, Laufer S, Goettert M . A Highly Selective In Vitro JNK3 Inhibitor, FMU200, Restores Mitochondrial Membrane Potential and Reduces Oxidative Stress and Apoptosis in SH-SY5Y Cells. Int J Mol Sci. 2021; 22(7). PMC: 8037381. DOI: 10.3390/ijms22073701. View

14.

An J, Chen B, Kang X, Zhang R, Guo Y, Zhao J . Neuroprotective effects of natural compounds on LPS-induced inflammatory responses in microglia. Am J Transl Res. 2020; 12(6):2353-2378. PMC: 7344058. View

15.

Carboni S, Boschert U, Gaillard P, Gotteland J, Gillon J, Vitte P . AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils. Br J Pharmacol. 2007; 153(1):157-63. PMC: 2199388. DOI: 10.1038/sj.bjp.0707574. View

16.

Dugger B, Dickson D . Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 9(7). PMC: 5495060. DOI: 10.1101/cshperspect.a028035. View

17.

Kaminska B . MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005; 1754(1-2):253-62. DOI: 10.1016/j.bbapap.2005.08.017. View

18.

Engin A . Bile Acid Toxicity and Protein Kinases. Adv Exp Med Biol. 2021; 1275:229-258. DOI: 10.1007/978-3-030-49844-3_9. View

19.

Merelli A, Repetto M, Lazarowski A, Auzmendi J . Hypoxia, Oxidative Stress, and Inflammation: Three Faces of Neurodegenerative Diseases. J Alzheimers Dis. 2020; 82(s1):S109-S126. DOI: 10.3233/JAD-201074. View

20.

Deng S, Jin P, Sherchan P, Liu S, Cui Y, Huang L . Recombinant CCL17-dependent CCR4 activation alleviates neuroinflammation and neuronal apoptosis through the PI3K/AKT/Foxo1 signaling pathway after ICH in mice. J Neuroinflammation. 2021; 18(1):62. PMC: 7923481. DOI: 10.1186/s12974-021-02112-3. View